25609060	1019	Di Stefano AL	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.	Clinical cancer research 	2015	19
25536104	1029	Churi CR	Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.	PloS one	2014	40
21881046	1050	Shen Y	Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.	Blood	2011	63
22417203	1050	Patel JP	Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.	The New England journal of medicine	2012	352
21670448	1788	Thol F	Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.	Journal of clinical oncology 	2011	77
21828135	1788	Jankowska AM	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.	Blood	2011	80
23632886	1788	Gaidzik VI	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).	Blood	2013	31
24142997	1788	Luthra R	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.	Haematologica	2014	30
24522528	1788	Shlush LI	Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.	Nature	2014	220
24699305	1788	Im AP	DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.	Leukemia	2014	37
22025148	1956	Lai A	Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.	Journal of clinical oncology 	2011	91
23391413	1956	Voss JS	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.	Human pathology	2013	38
25150284	1956	Labussière M	Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.	Neurology	2014	29
25468223	1956	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	26
25943888	1956	Aldape K	Glioblastoma: pathology, molecular mechanisms and markers.	Acta neuropathologica	2015	25
26354927	1956	Dubbink HJ	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.	Neuro-oncology	2016	14
25608663	2263	Sia D	Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.	Nature communications	2015	29
26190651	2475	Fu X	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.	Cell metabolism	2015	15
22661320	3021	Khuong-Quang DA	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.	Acta neuropathologica	2012	142
26061753	3075	Eckel-Passow JE	Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.	The New England journal of medicine	2015	135
24366912	3091	Chesnelong C	Lactate dehydrogenase A silencing in IDH mutant gliomas.	Neuro-oncology	2014	23
18772396	3417	Parsons DW	An integrated genomic analysis of human glioblastoma multiforme.	Science	2008	1466
19228619	3417	Yan H	IDH1 and IDH2 mutations in gliomas.	The New England journal of medicine	2009	972
19246647	3417	Watanabe T	IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.	The American journal of pathology	2009	185
19378339	3417	Kang MR	Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers.	International journal of cancer	2009	86
19554337	3417	Hartmann C	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.	Acta neuropathologica	2009	219
19636000	3417	Sanson M	Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.	Journal of clinical oncology 	2009	178
19657110	3417	Mardis ER	Recurring mutations found by sequencing an acute myeloid leukemia genome.	The New England journal of medicine	2009	605
19737147	3417	Ohgaki H	Genetic alterations and signaling pathways in the evolution of gliomas.	Cancer science	2009	99
19755387	3417	Nobusawa S	IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.	Clinical cancer research 	2009	117
19805672	3417	Weller M	Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.	Journal of clinical oncology 	2009	135
19935646	3417	Dang L	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.	Nature	2009	672
20097881	3417	Chou WC	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.	Blood	2010	56
20127344	3417	Bleeker FE	The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.	Acta neuropathologica	2010	68
20142433	3417	Gross S	Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.	The Journal of experimental medicine	2010	183
20160062	3417	van den Bent MJ	IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.	Clinical cancer research 	2010	88
20171147	3417	Ward PS	The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.	Cancer cell	2010	426
20368543	3417	Marcucci G	IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.	Journal of clinical oncology 	2010	179
20399149	3417	Noushmehr H	Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.	Cancer cell	2010	587
20410924	3417	Pardanani A	IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.	Leukemia	2010	41
20427748	3417	Labussière M	All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.	Neurology	2010	56
20508616	3417	Tefferi A	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.	Leukemia	2010	72
20513808	3417	Reitman ZJ	Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.	Journal of the National Cancer Institute	2010	101
20567020	3417	Paschka P	IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.	Journal of clinical oncology 	2010	152
20625116	3417	Boissel N	Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.	Journal of clinical oncology 	2010	45
20805365	3417	Schnittger S	IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.	Blood	2010	41
20975057	3417	Houillier C	IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.	Neurology	2010	84
21075857	3417	Kim YH	Molecular classification of low-grade diffuse gliomas.	The American journal of pathology	2010	43
21088844	3417	Hartmann C	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.	Acta neuropathologica	2010	98
21129061	3417	von Deimling A	The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations.	Brain pathology	2011	41
21130701	3417	Figueroa ME	Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.	Cancer cell	2010	586
21163902	3417	Christensen BC	DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.	Journal of the National Cancer Institute	2011	89
21289278	3417	Reitman ZJ	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.	Proceedings of the National Academy of Sciences of the United States of America	2011	143
21326614	3417	Jin G	2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.	PloS one	2011	47
21598255	3417	Amary MF	IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.	The Journal of pathology	2011	161
22015945	3417	Pope WB	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.	Journal of neuro-oncology	2012	57
22052461	3417	Jin SG	5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.	Cancer research	2011	110
22180306	3417	Borger DR	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.	The oncologist	2012	126
22238332	3417	Andronesi OC	Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.	Science translational medicine	2012	78
22238333	3417	Elkhaled A	Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.	Science translational medicine	2012	50
22270850	3417	Bleeker FE	Recent advances in the molecular understanding of glioblastoma.	Journal of neuro-oncology	2012	36
22281806	3417	Choi C	2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.	Nature medicine	2012	130
22343889	3417	Turcan S	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.	Nature	2012	385
22343901	3417	Lu C	IDH mutation impairs histone demethylation and results in a block to cell differentiation.	Nature	2012	379
22415316	3417	Gorovets D	IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.	Clinical cancer research 	2012	40
22829908	3417	Orr BA	Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma.	PloS one	2012	39
22899282	3417	Duncan CG	A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.	Genome research	2012	48
22990979	3417	Zhang W	Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme.	Cancer	2013	32
23071358	3417	Yang H	IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.	Clinical cancer research 	2012	46
23090983	3417	Yan W	Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group.	Neuro-oncology	2012	46
23095825	3417	Weller M	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.	Neuro-oncology	2012	31
23115158	3417	Li S	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.	Neuro-oncology	2013	30
23209033	3417	Ohgaki H	The definition of primary and secondary glioblastoma.	Clinical cancer research 	2013	107
23558173	3417	Wang F	Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.	Science	2013	152
23641016	3417	DiNardo CD	Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.	Blood	2013	35
23896276	3417	Weller M	Molecular neuro-oncology in clinical practice: a new horizon.	The Lancet. Oncology	2013	30
23954893	3417	Chaturvedi A	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.	Blood	2013	43
24068788	3417	Wick W	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.	Neurology	2013	31
24077805	3417	Borodovsky A	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.	Oncotarget	2013	31
24305719	3417	Beiko J	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.	Neuro-oncology	2014	36
24333121	3417	Emadi A	Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.	Experimental hematology	2014	32
24478380	3417	Borger DR	Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.	Clinical cancer research 	2014	23
24722048	3417	Killela PJ	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.	Oncotarget	2014	45
24810474	3417	Cai J	ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.	Oncotarget	2014	22
25043048	3417	Schumacher T	A vaccine targeting mutant IDH1 induces antitumour immunity.	Nature	2014	73
25091696	3417	Tang X	A joint analysis of metabolomics and genetics of breast cancer.	Breast cancer research 	2014	26
25143301	3417	Sahm F	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.	Acta neuropathologica	2014	32
25599133	3417	Chan SM	Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.	Nature medicine	2015	41
25701198	3417	Olar A	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.	Acta neuropathologica	2015	17
25783747	3417	Weller M	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.	Acta neuropathologica	2015	26
26124478	3417	Sandmann T	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.	Journal of clinical oncology 	2015	38
26669865	3417	Emir UE	Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.	Cancer research	2016	14
27005468	3417	Dang L	IDH mutations in cancer and progress toward development of targeted therapeutics.	Annals of oncology 	2016	16
27270107	3417	Wang J	Clonal evolution of glioblastoma under therapy.	Nature genetics	2016	15
27806376	3417	Tirosh I	Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.	Nature	2016	17
20847235	3418	Kranendijk M	IDH2 mutations in patients with D-2-hydroxyglutaric aciduria.	Science	2010	47
22215888	3418	Cairns RA	IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.	Blood	2012	80
24065766	3418	Lu C	Induction of sarcomas by mutant IDH2.	Genes and development	2013	35
24154961	7015	Koelsche C	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.	Acta neuropathologica	2013	36
23417712	29072	Fontebasso AM	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.	Acta neuropathologica	2013	57
20880116	171023	Gelsi-Boyer V	ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.	British journal of haematology	2010	46
21576631	171023	Thol F	Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.	Journal of clinical oncology 	2011	59
22489043	171023	Brecqueville M	Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.	Genes, chromosomes and cancer	2012	39
22898539	171023	Shih AH	The role of mutations in epigenetic regulators in myeloid malignancies.	Nature reviews. Cancer	2012	186
23349007	171023	Tefferi A	Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.	American journal of hematology	2013	27
23619563	171023	Vannucchi AM	Mutations and prognosis in primary myelofibrosis.	Leukemia	2013	79
23640996	171023	Abdel-Wahab O	Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.	Blood	2013	42
23690417	171023	Itzykson R	Prognostic score including gene mutations in chronic myelomonocytic leukemia.	Journal of clinical oncology 	2013	70
23958953	171023	Schwaab J	Comprehensive mutational profiling in advanced systemic mastocytosis.	Blood	2013	28
24045501	171023	Traina F	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.	Leukemia	2014	46
24549259	171023	Guglielmelli P	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.	Leukemia	2014	23
